<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0016.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0018.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="bmt"><a id="h125" class="calibre8"></a><a id="page_11-1" class="calibre8"></a><a href="part0003.html#rh139" class="calibre8">ICU MEDICATIONS</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre20"/>
<col class="calibre20"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th3" rowspan="2"><p class="tbodyc"><b class="calibre7">Drug</b></p></td>
<td class="th3" rowspan="2"><p class="tbodyc"><b class="calibre7">Class</b></p></td>
<td class="th4" colspan="2"><p class="tbodyc"><b class="calibre7">Dose</b></p></td>
</tr>
<tr class="calibre15">
<td class="th4"><p class="tbodyc"><b class="calibre7">per kg</b></p></td>
<td class="th4"><p class="tbodyc"><b class="calibre7">average</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="4"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Pressors, Inotropes, and Chronotropes</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Phenylephrine</p></td>
<td class="th1"><p class="tbodyc">α<sub class="calibre17">1</sub></p></td>
<td class="th1" colspan="2"><p class="tbodyc">10–300 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Norepinephrine</p></td>
<td class="th1"><p class="tbodyc">α<sub class="calibre17">1</sub> &gt;β<sub class="calibre17">1</sub></p></td>
<td class="th1" colspan="2"><p class="tbodyc">1–40 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Vasopressin</p></td>
<td class="th1"><p class="tbodyc">V<sub class="calibre17">1</sub></p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.01–0.1 U/min (usually &lt;0.04)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Epinephrine</p></td>
<td class="th1"><p class="tbodyc">α<sub class="calibre17">1</sub>, α<sub class="calibre17">2</sub>, β<sub class="calibre17">1</sub>, β<sub class="calibre17">2</sub></p></td>
<td class="th1" colspan="2"><p class="tbodyc">2–20 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Isoproterenol</p></td>
<td class="th1"><p class="tbodyc">β<sub class="calibre17">1</sub>, β<sub class="calibre17">2</sub></p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.1–10 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Dopamine</p></td>
<td class="th1"><p class="tbodyc">D</p>
<p class="tbodyc">β, D</p>
<p class="tbodyc">α, β, D</p></td>
<td class="th1"><p class="tbodyc">0.5–2 μg/kg/min</p>
<p class="tbodyc">2–10 μg/kg/min</p>
<p class="tbodyc">&gt;10 μg/kg/min</p></td>
<td class="th1"><p class="tbodyc">50–200 μg/min</p>
<p class="tbodyc">200–500 μg/min</p>
<p class="tbodyc">500–1000 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Dobutamine</p></td>
<td class="th1"><p class="tbodyc">β<sub class="calibre17">1</sub> &gt;β<sub class="calibre17">2</sub></p></td>
<td class="th1"><p class="tbodyc">2–20 μg/kg/min</p></td>
<td class="th1"><p class="tbodyc">50–1000 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Milrinone</p></td>
<td class="th1"><p class="tbodyc">PDE</p></td>
<td class="th1"><p class="tbodyc">± 50 μg/kg over 10 min then 0.25–0.75 μg/kg/min</p></td>
<td class="th1"><p class="tbodyc">3–4 mg over 10 min then 20–50 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="4"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Vasodilators</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nitroglycerin</p></td>
<td class="th1"><p class="tbodyc">NO</p></td>
<td class="th1" colspan="2"><p class="tbodyc">5–500 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nitroprusside</p></td>
<td class="th1"><p class="tbodyc">NO</p></td>
<td class="th1"><p class="tbodyc">0.25–10 μg/kg/min</p></td>
<td class="th1"><p class="tbodyc">10–800 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Labetalol</p></td>
<td class="th1"><p class="tbodyc">α<sub class="calibre17">1</sub>, β<sub class="calibre17">1</sub>, and β<sub class="calibre17">2</sub> blocker</p></td>
<td class="th1" colspan="2"><p class="tbodyc">20–80 mg q10min or 10–120 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fenoldopam</p></td>
<td class="th1"><p class="tbodyc">D</p></td>
<td class="th1"><p class="tbodyc">0.1–1.6 μg/kg/min</p></td>
<td class="th1"><p class="tbodyc">10–120 μg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Clevidipine</p></td>
<td class="th1"><p class="tbodyc">CCB</p></td>
<td class="th1" colspan="2"><p class="tbodyc">1–32 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Epoprostenol</p></td>
<td class="th1"><p class="tbodyc">vasodilator</p></td>
<td class="th1" colspan="2"><p class="tbodyc">2–20 ng/kg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="4"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Antiarrhythmics</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Amiodarone</p></td>
<td class="th1"><p class="tbodyc">K et al. (Class III)</p></td>
<td class="th1" colspan="2"><p class="tbodyc">150 mg over 10 min, then 1 mg/min × 6 h, then 0.5 mg/min × 18 h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lidocaine</p></td>
<td class="th1"><p class="tbodyc">Na channel (Class IB)</p></td>
<td class="th1"><p class="tbodyc">1–1.5 mg/kg then</p>
<p class="tbodyc">1–4 mg/min</p></td>
<td class="th1"><p class="tbodyc">100 mg then</p>
<p class="tbodyc">1–4 mg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Procainamide</p></td>
<td class="th1"><p class="tbodyc">Na channel (Class IA)</p></td>
<td class="th1"><p class="tbodyc">17 mg/kg over 60 min</p>
<p class="tbodyc">then 1–4 mg/min</p></td>
<td class="th1"><p class="tbodyc">1 g over 60 min then 1–4 mg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ibutilide</p></td>
<td class="th1"><p class="tbodyc">K channel (Class III)</p></td>
<td class="th1" colspan="2"><p class="tbodyc">1 mg over 10 min,</p>
<p class="tbodyc">may repeat × 1</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Propranolol</p></td>
<td class="th1"><p class="tbodyc">β blocker</p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.5–1 mg q5min then 1–10 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Esmolol</p></td>
<td class="th1"><p class="tbodyc">β<sub class="calibre17">1</sub> &gt;β<sub class="calibre17">2</sub> blocker</p></td>
<td class="th1"><p class="tbodyc">500–1000 μg/kg</p>
<p class="tbodyc">then 50–200 μg/kg/min</p></td>
<td class="th1"><p class="tbodyc">20–40 mg over 1 min then 2–20 mg/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Verapamil</p></td>
<td class="th1"><p class="tbodyc">CCB</p></td>
<td class="th1" colspan="2"><p class="tbodyc">2.5–5 mg over 1–2′, repeat 5–10 mg in 15–30′ prn 5–20 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Diltiazem</p></td>
<td class="th1"><p class="tbodyc">CCB</p></td>
<td class="th1"><p class="tbodyc">0.25 mg/kg over 2 min reload 0.35 mg/kg × 1 prn then 5–15 mg/h</p></td>
<td class="th1"><p class="tbodyc">20 mg over 2 min reload 25 mg × 1 prn then 5–15 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Adenosine</p></td>
<td class="th1"><p class="tbodyc">purinergic</p></td>
<td class="th1" colspan="2"><p class="tbodyc">6 mg rapid push; if no response: 12 mg → 12–18 mg</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="4"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Sedation</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Morphine</p></td>
<td class="th1"><p class="tbodyc">opioid</p></td>
<td class="th1" colspan="2"><p class="tbodyc">1–30 (in theory, unlimited) mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fentanyl</p></td>
<td class="th1"><p class="tbodyc">opioid</p></td>
<td class="th1" colspan="2"><p class="tbodyc">50–100 μg then 50–800 (? unlimited) μg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Propofol</p></td>
<td class="th1"><p class="tbodyc">anesthetic</p></td>
<td class="th1"><p class="tbodyc">1–3 mg/kg then</p>
<p class="tbodyc">0.3–5 mg/kg/h</p></td>
<td class="th1"><p class="tbodyc">50–200 mg then 20–400 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Dexmedetomidine</p></td>
<td class="th1"><p class="tbodyc">α<sub class="calibre17">2</sub> agonist</p></td>
<td class="th1" colspan="2"><p class="tbodyc">1 μg/kg over 10 min → 0.2–0.7 μg/kg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Diazepam</p></td>
<td class="th1"><p class="tbodyc">BDZ</p></td>
<td class="th1" colspan="2"><p class="tbodyc">1–5 mg q1–2h then q6h prn</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Midazolam</p></td>
<td class="th1"><p class="tbodyc">BDZ</p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.5–2 mg q5min prn; 0.02–0.1 mg/kg/h or 1–10 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lorazepam</p></td>
<td class="th1"><p class="tbodyc">BDZ</p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.01–0.1 mg/kg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Naloxone</p></td>
<td class="th1"><p class="tbodyc">opioid antag.</p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.4–2 mg q2–3min to total of 10 mg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Flumazenil</p></td>
<td class="th1"><p class="tbodyc">BDZ antag.</p></td>
<td class="th1" colspan="2"><p class="tbodyc">0.2 mg over 30 sec then 0.3 mg over 30 sec prn may repeat 0.5 mg over 30 sec to total of 3 mg</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="4"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Miscellaneous</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Aminophylline</p></td>
<td class="th1"><p class="tbodyc">PDE</p></td>
<td class="th1"><p class="tbodyc">5.5 mg/kg over 20 min then 0.5–1 mg/kg/h</p></td>
<td class="th1"><p class="tbodyc">250–500 mg</p>
<p class="tbodyc">then 10–80 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Octreotide</p></td>
<td class="th1"><p class="tbodyc">somatostatin analog</p></td>
<td class="th1" colspan="2"><p class="tbodyc">50 μg then 50 μg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Glucagon</p></td>
<td class="th1"><p class="tbodyc">hormone</p></td>
<td class="th1" colspan="2"><p class="tbodyc">3–10 mg IV slowly over 3–5 min then 3–5 mg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Mannitol</p></td>
<td class="th1"><p class="tbodyc">osmole</p></td>
<td class="th1" colspan="2"><p class="tbodyc">1.5–2 g/kg over 30–60 min repeat q6–12h to keep osm 310–320</p></td>
</tr>
</tbody>
</table>
<div class="cap">
<p class="caption"><a id="page_11-2" class="calibre4"></a><a id="fig11-1" class="calibre4"></a><b class="calibre7">Figure 11-1</b> ACLS pulmonary edema, hypotension or shock algorithm</p>
<p class="imagef1"><img src="../images/00111.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(Adapted from ACLS 2005 Guidelines)</p>
<h2 class="bmt"><a id="h126" class="calibre8"></a><a id="page_11-3" class="calibre8"></a><a href="part0003.html#rh140" class="calibre8">ANTIBIOTICS</a></h2>
<p class="centerb"><i class="calibre6">The following tables of spectra of activity for different antibiotics are generalizations.<br class="calibre1"/>Sensitivity data at your own institution should be used to guide therapy.</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre18"/>
<col class="calibre18"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="3"><p class="tbodyc"><b class="calibre7">Penicillins</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Generation</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Properties</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Spectrum</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Natural</b> (penicillin)</p></td>
<td class="th1"><p class="tbody">Active vs. many GPC, GPR, anaerobes (not <i class="calibre6">Bacteroides</i>), some Gram ⊖ coccobacilli &amp; Gram ⊖ diplococci</p></td>
<td class="th1"><p class="tbody">Most streptococci, many enterococci, <i class="calibre6">Listeria, C. acnes, Pasteurella, Actinomyces</i>, syphilis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Anti-staph</b> (eg, nafcillin)</p></td>
<td class="th1"><p class="tbody">Active vs. PCNase-producing Staph Little activity vs. Gram ⊖</p></td>
<td class="th1"><p class="tbody">Staphylococci (except MRSA) Streptococci</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Amino</b> (eg, ampicillin)</p></td>
<td class="th1"><p class="tbody">Penetrate porin channel of Gram ⊖</p>
<p class="tbody">Not stable against PCNases</p></td>
<td class="th1"><p class="tbody">PCN plus <i class="calibre6">E. coli, Proteus, H. influenzae, Salmonella, Shigella</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Extended</b> (eg, piperacillin)</p></td>
<td class="th1"><p class="tbody">Penetrate porin channel of Gram ⊖ More resistant to PCNases</p></td>
<td class="th1"><p class="tbody">Most GNR incl. <i class="calibre6">Enterobacter, Pseudomonas, Serratia</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">β-lact. inhib.</b> (eg, sulbactam, clavulanate) with PCN derivative</p></td>
<td class="th1"><p class="tbody">Inhibits some plasma-mediated β-lactamases</p></td>
<td class="th1"><p class="tbody">Adds staph (not MRSA), most PCN-R anaerobes, &amp; some GNR (<i class="calibre6">H. flu, M. cat</i>, some enterics); intrinsic activity against <i class="calibre6">Acinetobacter</i></p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre18"/>
<col class="calibre18"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="3"><p class="tbodyc"><b class="calibre7">Cephalosporins</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="3" class="th1"><p class="tbodyc"><i class="calibre6">Resistant to most penicillin</i> b<i class="calibre6">-lactamases. No activity vs. enterococci.</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Generation</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Spectrum</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Indications</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">1<sup class="calibre27">st</sup> (eg, cefazolin)</p></td>
<td class="th1"><p class="tbody">Most GPC (incl. staph &amp; strep, not MRSA); some GNR (incl. <i class="calibre6">E. coli, Proteus, Klebsiella</i>)</p></td>
<td class="th1"><p class="tbody">Used for surgical Ppx &amp; skin infxns</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">2</b><sup class="calibre27">nd</sup> (eg, cefuroxime, cefotetan)</p></td>
<td class="th1"><p class="tbody">↓ activity vs. GPC, ↑ vs. GNR. 2 subgroups:</p>
<p class="tbody">Resp: <i class="calibre6">H. influenzae</i> &amp; <i class="calibre6">M. catarrhalis</i></p>
<p class="tbody">GI/GU: ↑ activity vs. <i class="calibre6">B. fragilis</i></p></td>
<td class="th1"><p class="tbody">PNA/COPD flare</p>
<p class="tbody">Abdominal infxns</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">3</b><sup class="calibre27">rd</sup> (eg, ceftriaxone, ceftazidime)</p></td>
<td class="th1"><p class="tbody">Broad activity vs. GNR (not ESBL), streptococci, &amp; some anaerobes. Ceftazidime active vs. <i class="calibre6">Pseudomonas</i>, less vs. strep</p></td>
<td class="th1"><p class="tbody">PNA, sepsis, meningitis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">4</b><sup class="calibre27">th</sup> (eg, cefepime)</p></td>
<td class="th1"><p class="tbody">↑ resistance to β-lactamases (incl. <i class="calibre6">Enterobacter</i>)</p></td>
<td class="th1"><p class="tbody">Similar to 3<sup class="calibre27">rd</sup> gen. MonoRx for nonlocalizing febrile neutropenia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">5</b><sup class="calibre27">th</sup> (eg, ceftaroline)</p></td>
<td class="th1"><p class="tbody">Only class of cephalosporin with MRSA activity. GN activity similar to ceftriaxone. NOT active vs. <i class="calibre6">Pseudomonas</i>.</p></td>
<td class="th1"><p class="tbody">MRSA. Not 1<sup class="calibre27">st</sup> line for MRSA bacteremia.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Combination</b> (eg, ceftolozane-tazobactam, ceftazidime- avibactam)</p></td>
<td class="th1"><p class="tbody">MDR GNRs, incl. <i class="calibre6">Pseudomonas</i>. Ceftaz-avi has activity vs. some carbapenemases.</p></td>
<td class="th1"><p class="tbody">Complicated UTIs, complicated intra-abdominal infections.</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre33"/>
<col class="calibre33"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="3"><p class="tbodyc"><b class="calibre7">Other Beta-Lactams</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Class</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Properties</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Spectrum</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Carbapenems</b> (eg, imipenem)</p></td>
<td class="th1"><p class="tbody">Resistant to most β-lactamases</p></td>
<td class="th1"><p class="tbody">Most Gram ⊕ &amp; ⊖, incl. anaerobes; <i class="calibre6">not</i> MRSA or VRE</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Monobactams</b> (aztreonam)</p></td>
<td class="th1"><p class="tbody">Active vs. Gram ⊖ but not Gram ⊕</p></td>
<td class="th1"><p class="tbody">Gram ⊖ bacterial infxn in Pt w/ PCN or Ceph allergy</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="2"><p class="tbodyc"><b class="calibre7">Other Antibiotics</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Antibiotic</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Spectrum</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vancomycin</b></p></td>
<td class="th1"><p class="tbodyh">Gram ⊕ bacteria incl. MRSA, PCNase-producing pneumococci and enterococci (except VRE)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Linezolid</b></p></td>
<td rowspan="2" class="th1"><p class="tbodyh">GPC incl. MRSA &amp; VRE (check susceptibility for VRE)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Daptomycin</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Quinolones</b></p></td>
<td class="th1"><p class="tbodyh">GNR &amp; atypicals. Levo and esp moxi ↑ activity vs. Gram ⊕.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aminoglycosides</b></p></td>
<td class="th1"><p class="tbodyh">GNR. Synergy w/ cell-wall active abx (β-lactam, vanco) vs. GPC. ↓ activity in low pH (eg, abscess). No activity vs. anaerobes.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Macrolides</b></p></td>
<td class="th1"><p class="tbodyh">GPC, some respiratory Gram ⊖, atypicals</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">TMP/SMX</b></p></td>
<td class="th1"><p class="tbodyh">Most enteric GNR, Staph incl CA-MRSA, <i class="calibre6">Stenotrophomonas</i>, <i class="calibre6">Nocardia, Toxo</i>, <i class="calibre6">Pneumocystis</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Clindamycin</b></p></td>
<td class="th1"><p class="tbodyh">Most Gram ⊕ (except enterococci) &amp; anaerobes (increasing resistance, especially GI)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Metronidazole</b></p></td>
<td class="th1"><p class="tbodyh">Almost all anaerobic Gram ⊖, most anaerobic Gram ⊕, some protozoa (<i class="calibre6">Entamoeba</i>, <i class="calibre6">Trichomonas</i>, et al.)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Doxycycline</b></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Rickettsia, Ehrlichia, Anaplasma, Chlamydia, Mycoplasma, Nocardia</i>, Lyme; many Staph and GNR</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Tigecycline</b></p></td>
<td class="th1"><p class="tbodyh">Many GPC incl. MRSA &amp; VRE; most GNR incl. ESBL but not <i class="calibre6">Pseudomonas</i> or <i class="calibre6">Proteus</i>; most anaerobes</p></td>
</tr>
</tbody>
</table>
<p class="imaget"><a id="page_11-4" class="calibre4"></a><img src="../images/00112.jpeg" alt="" class="calibre5"/></p>
<h2 class="bmt"><a id="h127" class="calibre8"></a><a id="page_11-5" class="calibre8"></a><a href="part0003.html#rh141" class="calibre8">FORMULAE AND QUICK REFERENCE</a></h2>
<p class="h2d">C<small class="calibre31">ARDIOLOGY</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre21"/>
<col class="calibre20"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th4"><p class="tbody"><b class="calibre7">Hemodynamic Parameters</b></p></td>
<td class="th4"><p class="tbodyc"><b class="calibre7">Normal Value</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mean arterial pressure</b> <img src="../images/00113.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">70–100 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Heart rate (HR)</b></p></td>
<td class="th1"><p class="tbodyc">60–100 bpm</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Right atrial pressure (RA)</b></p></td>
<td class="th1"><p class="tbodyc">≤6 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Right ventricular (RV)</b></p></td>
<td class="th1"><p class="tbodyc">systolic 15–30 mmHg</p>
<p class="tbodyc">diastolic 1–8 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary artery (PA)</b></p></td>
<td class="th1"><p class="tbodyc">systolic 15–30 mmHg</p>
<p class="tbodyc">mean 9–18 mmHg</p>
<p class="tbodyc">diastolic 6–12 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary capillary wedge pressure</b> (PCWP)</p></td>
<td class="th1"><p class="tbodyc">≤12 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac output</b> (CO)</p></td>
<td class="th1"><p class="tbodyc">4–8 L/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac index</b> <img src="../images/00114.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">2.6–4.2 L/min/m<sup class="calibre27">2</sup></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Stroke volume</b> <img src="../images/00115.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">60–120 mL/contraction</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Stroke volume index</b> <img src="../images/00116.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">40–50 mL/contraction/m<sup class="calibre27">2</sup></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">Systemic vascular resistance</b> (SVR)</p>
<p class="tbodyc"><img src="../images/00117.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">800–1200 dynes × sec/cm<sup class="calibre27">5</sup></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">Pulmonary vascular resistance</b> (PVR)</p>
<p class="tbodyc"><img src="../images/00118.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">120–250 dynes × sec/cm<sup class="calibre27">5</sup></p></td>
</tr>
</tbody>
</table>
<p class="tfn">“Rule of 6s” for PAC: RA ≤6, RV ≤30/6, PA ≤30/12, WP ≤12. Nb 1 mmHg = 1.36 cm water or blood.</p>
<p class="h2e">Fick cardiac output</p>
<p class="noindent1">Oxygen consumption (L/min) = CO (L/min) × arteriovenous (AV) oxygen difference</p>
<p class="noindent1">CO = oxygen consumption/AV oxygen difference</p>
<p class="noindent1">Oxygen consumption must be measured (can estimate w/ 125 mL/min/m<sup class="calibre19">2</sup>, but inaccurate)</p>
<p class="noindent1">AV oxygen difference = Hb (g/dL) × 10 (dL/L) × 1.36 (mL O<sub class="calibre10">2</sub>/g of Hb) × (S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>–S<sub class="calibre10">MV</sub>O<sub class="calibre10">2</sub>)</p>
<p class="bl">S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> is measured in any arterial sample (usually 93–98%)</p>
<p class="bl">S<sub class="calibre10">MV</sub>O<sub class="calibre10">2</sub> (mixed venous O<sub class="calibre10">2</sub>) is measured in RA, RV, or PA (assuming no shunt) (nl ~75%)</p>
<p class="image1"><img src="../images/00119.jpeg" alt="" class="calibre5"/></p>
<p class="h2e">Assessment of RV function <span class="calibre9">(<i class="calibre6">Circ</i> 2017;136:314)</span></p>
<p class="toc">PAPi = Pulmonary artery pulsatility index = [PA systolic – PA diastolic] / RA pressure ≤0.9 predicts RV failure in acute MI; &lt;1.85 predicts RV failure after LVAD</p>
<p class="h2e">Shunts</p>
<p class="image1"><img src="../images/00120.jpeg" alt="" class="calibre5"/></p>
<p class="h2e">Valve equations</p>
<p class="noindent1">Simplified Bernoulli: Pressure gradient (∇P) = 4 × v<sup class="calibre19">2</sup> (where v = peak flow velocity)</p>
<p class="noindent1">Continuity (conservation of flow): Area<sub class="calibre10">1</sub> × Velocity<sub class="calibre10">1</sub> = A<sub class="calibre10">2</sub> × V<sub class="calibre10">2</sub> (where 1 &amp; 2 different points)</p>
<p class="image1"><img src="../images/00121.jpeg" alt="" class="calibre5"/></p>
<p class="image1"><img src="../images/00122.jpeg" alt="" class="calibre5"/></p>
<p class="h2d"><a id="page_11-6" class="calibre8"></a>P<small class="calibre31">ULMONARY</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="3"><p class="tbodyc"><b class="calibre7">Chest Imaging (CXR &amp; CT) Patterns</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pattern</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Pathophysiology</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Ddx</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Consolidation</p></td>
<td class="th1"><p class="tbodyh">Radiopaque material in air space &amp; interstitium patent airway → “air bronchograms”</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Acute:</i> water <b class="calibre7">(pulm. edema)</b>, pus <b class="calibre7">(PNA), blood</b></p>
<p class="tbodyh"><i class="calibre6">Chronic:</i> neoplasm (BAC, lymphoma), aspiration, inflammatory (COP, eosinophilic PNA), PAP, granuloma (TB/fungal, alveolar sarcoid)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ground glass (CT easier than CXR)</p></td>
<td class="th1"><p class="tbodyh">Interstitial thickening or partial filling of alveoli (but vessels visible)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Acute:</i> pulm. edema, infxn (PCP, viral, resolving bact. PNA)</p>
<p class="tbodyh">Chronic: ILD</p>
<p class="tbodyh">w/o fibrosis: acute hypersens., DIP/RB, PAP</p>
<p class="tbodyh">w/ fibrosis: IPF</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Septal lines Kerley A &amp; B</p></td>
<td class="th1"><p class="tbodyh">Radiopaque material in septae</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Cardiogenic pulm. edema</b>, interstitial PNA viral, mycoplasma, lymphangitic tumor</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Reticular</p></td>
<td class="th1"><p class="tbodyh">Lace-like net (ILD)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">ILD</b> (esp. IPF, CVD, bleomycin, asbestos)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nodules</p></td>
<td class="th1"><p class="tbodyh">Tumor</p>
<p class="tbodyh">Granulomas</p>
<p class="tbodyh">Abscess</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Cavitary:</i> <b class="calibre7">Primary or metastatic cancer</b>, <b class="calibre7">TB</b> (react. or miliary), <b class="calibre7">fungus</b>, Wegener’s, RA <b class="calibre7">septic emboli</b>, PNA</p>
<p class="tbodyh"><i class="calibre6">Noncavitary:</i> any of above + <b class="calibre7">sarcoid</b>, hypersens. pneum., HIV, Kaposi’s sarcoma</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Wedge opac.</p></td>
<td class="th1"><p class="tbodyh">Peripheral infarct</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">PE</b>, cocaine, angioinv. aspergillus, Wegener’s</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Tree-in-bud (best on CT)</p></td>
<td class="th1"><p class="tbodyh">Inflammation of small airways</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Bronchopneumonia</b>, endobronchial TB/MAI, viral PNA, aspiration, ABPA, CF, asthma, COP</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hilar fullness</p></td>
<td class="th1"><p class="tbodyh">↑ LN or pulm. arteries</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Neoplasm</b> (lung, mets, lymphoma)</p>
<p class="tbodyh"><b class="calibre7">Infxn</b> (AIDS); <b class="calibre7">Granuloma</b> (sarcoid/TB/fungal)</p>
<p class="tbodyh">Pulmonary hypertension</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Upper lobe</p></td>
<td class="th1"><p class="tbodyh">n/a</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">TB</b>, fungal, sarcoid, hypersens. pneum., CF, XRT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lower lobe</p></td>
<td class="th1"><p class="tbodyh">n/a</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Aspiration</b>, bronchiect., IPF, RA, SLE, asbestos</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Peripheral</p></td>
<td class="th1"><p class="tbodyh">n/a</p></td>
<td class="th1"><p class="tbodyh">COP, IPF &amp; DIP, eos PNA, asbestosis</p></td>
</tr>
</tbody>
</table>
<p class="h2e">CXR in heart failure</p>
<p class="bl1"><span class="ft">•</span> ↑ cardiac silhouette (in systolic dysfxn, not in diastolic)</p>
<p class="bl1"><span class="ft">•</span> Pulmonary venous hypertension: cephalization of vessels (vessels size &gt;bronchi in upper lobes), peribronchial cuffing (fluid around bronchi seen on end → small circles), Kerley B lines (horizontal 1- to 2-cm lines at bases), ↑ vascular pedicle width, loss of sharp vascular margins, pleural effusions (~75% bilateral)</p>
<p class="bl1"><span class="ft">•</span> Pulmonary edema: ranges from ground glass to consolidation; often dependent and central, sparing outer third (“bat wing” appearance)</p>
<p class="noindent1"><b class="calibre7">Dead space</b> = lung units that are ventilated but not perfused</p>
<p class="noindent1"><b class="calibre7">Intrapulmonary shunt</b> = lung units that are perfused but not ventilated</p>
<p class="image1"><img src="../images/00123.jpeg" alt="" class="calibre5"/></p>
<p class="noindent1"><b class="calibre7">A-a gradient</b> = P<sub class="calibre10">A</sub>O<sub class="calibre10">2</sub> – P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> [normal A-a gradient ≈ 4 + (age/4)]</p>
<p class="noindent1"><b class="calibre7">Minute ventilation</b> (V<sub class="calibre10">E</sub>) = tidal volume (V<sub class="calibre10">T</sub>) × respiratory rate (RR) (nl 4–6 L/min)</p>
<p class="noindent1"><b class="calibre7">Tidal volume</b> (V<sub class="calibre10">T</sub>) = alveolar space (V<sub class="calibre10">A</sub>) + dead space (V<sub class="calibre10">D</sub>)</p>
<p class="image1"><img src="../images/00124.jpeg" alt="" class="calibre5"/></p>
<p class="h2d"><a id="page_11-7" class="calibre8"></a>G<small class="calibre31">ASTROENTEROLOGY</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre33"/>
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="4"><p class="tbodyc"><b class="calibre7">Modified Child-Turcotte-Pugh (CPS) Scoring System</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td colspan="3" class="th1"><p class="tbodyc"><b class="calibre7">Points Scored</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">1</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">2</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">3</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ascites</p></td>
<td class="th1"><p class="tbodyc">None</p></td>
<td class="th1"><p class="tbodyc">Easily controlled</p></td>
<td class="th1"><p class="tbodyc">Poorly controlled</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Encephalopathy</p></td>
<td class="th1"><p class="tbodyc">None</p></td>
<td class="th1"><p class="tbodyc">Grade 1 or 2</p></td>
<td class="th1"><p class="tbodyc">Grade 3 or 4</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Bilirubin (mg/dL)</p></td>
<td class="th1"><p class="tbodyc">&lt;2</p></td>
<td class="th1"><p class="tbodyc">2–3</p></td>
<td class="th1"><p class="tbodyc">&gt;3</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Albumin (g/dL)</p></td>
<td class="th1"><p class="tbodyc">&gt;3.5</p></td>
<td class="th1"><p class="tbodyc">2.8–3.5</p></td>
<td class="th1"><p class="tbodyc">&lt;2.8</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh">PT (sec &gt;control)</p>
<p class="tbodyh">or INR</p></td>
<td class="th1"><p class="tbodyc">&lt;4</p>
<p class="tbodyc">&lt;1.7</p></td>
<td class="th1"><p class="tbodyc">4–6</p>
<p class="tbodyc">1.8–2.3</p></td>
<td class="th1"><p class="tbodyc">&gt;6</p>
<p class="tbodyc">&gt;2.3</p></td>
</tr>
<tr class="calibre15">
<td colspan="4" class="th1"><p class="tbodyc"><b class="calibre7">Classification</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">A</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">B</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">C</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Total points</p></td>
<td class="th1"><p class="tbodyc">5–6</p></td>
<td class="th1"><p class="tbodyc">7–9</p></td>
<td class="th1"><p class="tbodyc">10–15</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">1-y survival</p></td>
<td class="th1"><p class="tbodyc">100%</p></td>
<td class="th1"><p class="tbodyc">80%</p></td>
<td class="th1"><p class="tbodyc">45%</p></td>
</tr>
</tbody>
</table>
<p class="h2d"><b class="calibre44">N<small class="calibre31">EPHROLOGY</small></b></p>
<p class="noindent1"><b class="calibre7">Anion gap</b> (AG) = Na – (Cl + HCO<sub class="calibre10">3</sub>) (normal = [alb] × 2.5; typically 12 ± 2 mEq)</p>
<p class="noindent1"><b class="calibre7">Delta-delta</b> (ΔΔ) = [Δ AG (ie, calc. AG – expected) / Δ HCO<sub class="calibre10">3</sub> (ie, 24 – measured HCO<sub class="calibre10">3</sub>)]</p>
<p class="noindent1"><b class="calibre7">Urine anion gap</b> (UAG) = (U<sub class="calibre10">Na</sub> + U<sub class="calibre10">K</sub>) – U<sub class="calibre10">Cl</sub></p>
<p class="image1"><img src="../images/00125.jpeg" alt="" class="calibre5"/></p>
<p class="h2d">H<small class="calibre31">EMATOLOGY</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="2"><p class="tbodyc"><b class="calibre7">Peripheral Smear Findings</b> (also see Photo Inserts)</p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Abnormalities and Diagnoses</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Size</b></p></td>
<td class="th1"><p class="tbodyh">normocytic vs. microcytic vs. macrocytic → see below</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Shape</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Anisocytosis</b> → unequal RBC size; <b class="calibre7">poikilocytosis</b> → irregular RBC shape acanthocytes = <b class="calibre7">spur</b> cells (irregular sharp projections) → liver disease</p>
<p class="tbodyh"><b class="calibre7">Bite</b> cells (removal of Heinz bodies by phagocytes) → G6PD deficiency echinocytes = <b class="calibre7">burr</b> cells (even, regular projections) → uremia, artifact</p>
<p class="tbodyh"><b class="calibre7">Pencil cell</b> → long, thin, hypochromic–very common in adv. iron deficiency</p>
<p class="tbodyh"><b class="calibre7">Rouleaux</b> → hyperglobulinemia (eg, multiple myeloma)</p>
<p class="tbodyh"><b class="calibre7">Schistocytes</b>, helmet cells → MAHA (eg, DIC, TTP/HUS), mechanical valve</p>
<p class="tbodyh"><b class="calibre7">Spherocytes</b> → HS, AIHA; <b class="calibre7">sickle</b> cells → sickle cell anemia</p>
<p class="tbodyh"><b class="calibre7">Stomatocyte</b> → central pallor appears as curved slit → liver disease, EtOH</p>
<p class="tbodyh"><b class="calibre7">Target</b> cells → liver disease, hemoglobinopathies, splenectomy</p>
<p class="tbodyh"><b class="calibre7">Tear drop</b> cells = dacryocytes → myelofibrosis, myelophthisic anemia, megaloblastic anemia, thalassemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Intra- RBC findings</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Basophilic stippling</b> (ribosomes) → abnl Hb, sideroblastic, megaloblastic</p>
<p class="tbodyh"><b class="calibre7">Heinz bodies</b> (denatured Hb) → G6PD deficiency, thalassemia</p>
<p class="tbodyh"><b class="calibre7">Howell-Jolly bodies</b> (nuclear fragments) → splenectomy or functional asplenia (eg, advanced sickle cell)</p>
<p class="tbodyh"><b class="calibre7">Nucleated</b> RBCs → hemolysis, extramedullary hematopoiesis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">WBC findings</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Blasts</b> → leukemia, lymphoma; <b class="calibre7">Auer rods</b> → acute myelogenous leukemia</p>
<p class="tbodyh"><b class="calibre7">Hypersegmented</b> (&gt;5 lobes) PMNs: megaloblastic anemia (B<sub class="calibre17">12</sub>/folate def.)</p>
<p class="tbodyh"><b class="calibre7">Pseudo-Pelger-Huët anomaly</b> (bilobed nucleus, “pince-nez”) → MDS</p>
<p class="tbodyh"><b class="calibre7">Toxic granules</b> (coarse, dark blue) and <b class="calibre7">Döhle bodies</b> (blue patches of dilated endoplasmic reticulum) → (sepsis, severe inflammation)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Platelet</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Clumping</b> → artifact, repeat plt count</p>
<p class="tbodyh"><b class="calibre7">#</b> → periph blood plt count ~10,000 plt for every 1 plt seen at hpf (100×)</p>
<p class="tbodyh"><b class="calibre7">Size</b> → MPV (mean platelet volume) enlarged in ITP</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">NEJM</i> 2005;353:498)</p>
<a id="page_11-8" class="calibre4"></a>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="2"><p class="tbodyc"><b class="calibre7">Heparin for Thromboembolism</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbodyc">80 U/kg bolus</p>
<p class="tbodyc">18 U/kg/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">PTT</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Adjustment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;40</p></td>
<td class="th1"><p class="tbodyc">bolus 5000 U, ↑ rate 300 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">40–49</p></td>
<td class="th1"><p class="tbodyc">bolus 3000 U, ↑ rate 200 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">50–59</p></td>
<td class="th1"><p class="tbodyc">↑ rate 150 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">60–85</p></td>
<td class="th1"><p class="tbodyc">no Δ</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">86–95</p></td>
<td class="th1"><p class="tbodyc">↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">96–120</p></td>
<td class="th1"><p class="tbodyc">hold 30 min, ↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&gt;120</p></td>
<td class="th1"><p class="tbodyc">hold 60 min, ↓ rate 150 U/h</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(Modified from <i class="calibre6">Chest</i> 2008;133:141S)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="2"><p class="tbodyc"><b class="calibre7">Heparin for ACS</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbodyc">60 U/kg bolus (max 4000 U)</p>
<p class="tbodyc">12 U/kg/h (max 1000 U/h)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">PTT</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Adjustment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">&lt;40</p></td>
<td class="th1"><p class="tbodyc">bolus 3000 U, ↑ rate 100 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">40–49</p></td>
<td class="th1"><p class="tbodyc">↑ rate 100 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">50–75</p></td>
<td class="th1"><p class="tbodyc">no Δ</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">76–85</p></td>
<td class="th1"><p class="tbodyc">↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">86–100</p></td>
<td class="th1"><p class="tbodyc">hold 30 min, ↓ rate 100 U/h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">&gt;100</p></td>
<td class="th1"><p class="tbodyc">hold 60 min, ↓ rate 200 U/h</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(Modified from <i class="calibre6">Circ</i> 2007;116:e148 &amp; <i class="calibre6">Chest</i> 2008;133:670)</p>
<p class="noindent1">✓ PTT q6h after every Δ (t. of heparin ~90 min) and then qd or bid once PTT is therapeutic</p>
<p class="noindent1">✓ CBC qd (to ensure Hct and plt counts are stable)</p>
<p class="imaget"><img src="../images/00126.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">(<i class="calibre6">Annals</i> 1997;126:133; <i class="calibre6">Archives</i> 1999;159:46) or, go to <a href="http://www.warfarindosing.org" class="calibre4">www.warfarindosing.org</a></p>
<p class="h2e">Warfarin-heparin overlap therapy</p>
<p class="bl1"><span class="ft">•</span> Indications: when failure to anticoagulate carries ↑ risk of morbidity or mortality (eg, DVT/PE, intracardiac thrombus)</p>
<p class="bl2"><span class="ft1">•    Rationale:</span> (1) Half-life of factor VII (3–6 h) is shorter than half-life of factor II (60–72 h);<br class="calibre1"/>∴ warfarin can elevate PT <i class="calibre6">before achieving a true antithrombotic state</i><br class="calibre1"/>(2) Protein C also has half-life less than that of factor II;<br class="calibre1"/>∴ theoretical concern of <i class="calibre6">hypercoagulable state</i> before antithrombotic state</p>
<p class="bl2"><span class="ft1">•    Method:</span> (1) Therapeutic PTT is achieved using heparin<br class="calibre1"/>(2) Warfarin therapy is initiated<br class="calibre1"/>(3) Heparin continued until INR therapeutic for ≥2 d and ≥4–5 d of warfarin (roughly corresponds to ~2 half-lives of factor II or a reduction to ~25%)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="2"><p class="tbodyc"><b class="calibre7">Common Warfarin-Drug Interactions</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drugs that</b> ↑ <b class="calibre7">PT</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Drugs that</b> ↓ <b class="calibre7">PT</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh">Amiodarone</p>
<p class="tbodyh">Antimicrobials: erythromycin, ? clarithro, ciprofloxacin, MNZ, sulfonamides</p>
<p class="tbodyh">Antifungals: azoles</p>
<p class="tbodyh">Acetaminophen, cimetidine, levothyroxine</p></td>
<td class="th1"><p class="tbodyh">Antimicrobials: rifampin</p>
<p class="tbodyh">CNS: barbiturates, carbamazepine, phenytoin (initial transient ↑ PT)</p>
<p class="tbodyh">Cholestyramine</p></td>
</tr>
</tbody>
</table>
<p class="h2d">E<small class="calibre31">NDOCRINOLOGY</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre28"/>
<col class="calibre28"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th4" colspan="4"><p class="tbodyc"><b class="calibre7">Examples of Various Cosyntropin Stimulation Test Results</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">0′</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">30′</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">60′</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Interpretation</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">5.3</p></td>
<td class="th1"><p class="tbodyc">15.5</p></td>
<td class="th1"><p class="tbodyc">23.2</p></td>
<td class="th1"><p class="tbody">Normal stimulation test</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">1.5</p></td>
<td class="th1"><p class="tbodyc">13.3</p></td>
<td class="th1"><p class="tbodyc">21.1</p></td>
<td class="th1"><p class="tbody">Acute central AI (eg, apoplexy or CNS bleed). Can look normal.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">1.2</p></td>
<td class="th1"><p class="tbodyc">1.5</p></td>
<td class="th1"><p class="tbodyc">2.0</p></td>
<td class="th1"><p class="tbody">1° AI (eg, Addisons or adrenal bleed). Flat or minimal stim.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">0.8</p></td>
<td class="th1"><p class="tbodyc">10.0</p></td>
<td class="th1"><p class="tbodyc">19.7</p></td>
<td class="th1"><p class="tbody">Acute effect of glucocorticoids: low initial value but stims &gt;threshold</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">5.3</p></td>
<td class="th1"><p class="tbodyc">7.2</p></td>
<td class="th1"><p class="tbodyc">8.9</p></td>
<td class="th1"><p class="tbody">Chronic 2° AI: some cortisol production and stim, but evidence of adrenal atrophy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">6.7</p></td>
<td class="th1"><p class="tbodyc">19.5</p></td>
<td class="th1"><p class="tbodyc">17.2</p></td>
<td class="th1"><p class="tbody">“Early peak” (fast metab): ~5% of Pts peak at 30’ rather than 60’</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">6.3</p></td>
<td class="th1"><p class="tbodyc">11.5</p></td>
<td class="th1"><p class="tbodyc">16.2</p></td>
<td class="th1"><p class="tbody">Equivocal test. Can occur due to mild AI, acute illness, liver disease, low cortisol binding protein, renal disease, etc.</p></td>
</tr>
</tbody>
</table>
<p class="h2d"><a id="page_11-9" class="calibre8"></a>N<small class="calibre31">EUROLOGY</small></p>
<p class="imaget"><img src="../images/00127.jpeg" alt="" class="calibre5"/></p>
<p class="h2d">O<small class="calibre31">THER</small></p>
<p class="imaget"><img src="../images/00128.jpeg" alt="" class="calibre5"/></p>
<h2 class="bmt"><a id="page_11-10" class="calibre8"></a>NOTES</h2>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0016.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0018.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
